#ASH18: Bluebird and Celgene didn’t ‘break’ their next-gen BCMA CAR-T, so now they’ll double down on the dose and root for real durability

After the latest round of data on bb2121 from bluebird and Celgene left some of the more, um, demanding analysts disappointed in terms of durability, the ante has been raised substantially on the bet they’re making on their second-gen CAR-T — bb21217.

Designed to rely more on memory cells to amp up the efficacy — a perfectly reasonable theory that relies heavily on mouse data for its proof-of-concept rationale — bb21217 debuted its first data snapshot at ASH on Sunday.

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 47,400+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,400+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->